Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609609 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL608185 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL608264 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL4312685 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL5240935 | 0.78 | CNR1 (0.43) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL25572001 | 0.78 | CNR1 (0.43) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL30706198 | 0.78 | CNR1 (0.43) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL9066841 | 0.78 | RECQL (0.49) | USP2SMN1; SMN2RECQLMAPTKDM4E | |
| SCHEMBL25572000 | 0.78 | CNR1 (0.43) | USP2SMN1; SMN2RECQLCHRM2CHRM4 | |
| SCHEMBL19853552 | 0.78 | CNR1 (0.41) | USP2SMN1; SMN2RECQLCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| EP-2755975-A1 | NEW ENZYME INHIBITOR COMPOUNDS | Proximagen Limited (GB) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038189-A1 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LTD. (GB) | 2013-03-21 | — | — | WO | disclosed |
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1552842-A1 | BICYCLIC PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | USP2 4807/4885SMN1; SMN2 4492/4885RECQL 2882/4885 |
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | XDH, MAOB, MAOA | USP2 626/4885SMN1; SMN2 2398/4885RECQL 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.